Single-Use Bioreactor Patents: Who Leads, Where the Gaps Are 2026
Single-Use Bioreactor Scale-Up Patents: Leaders, Filing Trends and Open Claim Space
One assignee, 14 records. The leader holds 14 records in a 25-company ranking where fifth place sits at 4 and tenth at 2 — a steep drop-off rather than a gradual tail. Filings reached 10 in 2017, the highest single year in the set, and the years since show fewer publications. Treat the most recent one or two years as understated: publication typically lags filing by around 18 months, so 2025-2026 records are still arriving.
- 1EMD MILLIPORE CORP14
- 2LONZA AG14
- 3ROSEMOUNT INC7
- 4GLOBAL LIFE SCIENCES SOLUTIONS USA LLC6
- 5ROSEMOUNT ANALYTICAL INC4
See the full single-use bioreactor scale-up analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on single-use bioreactor scale-up patents
Who holds the most patents on single-use bioreactor scale-up?
One assignee leads the 25-company ranking with 14 records, well ahead of fifth place at 4 and tenth place at 2. That gap indicates an early, broad filing push around core bag-mixing and vessel mechanics rather than a field where filings are spread evenly. Anyone entering this space should check that leader’s portfolio specifically rather than assuming the field is fragmented.
What technology areas are most heavily claimed in single-use bioreactor patents?
Bioreactor and enzyme-apparatus claims under IPC class C12M appear on 78.0% of the 50 records in this dataset, and mixing/stirring claims under B01F appear on 42.0%. Catalysis, brewing-specific and microorganism-specific claims each sit at 4.0% or below. Practically, this means vessel geometry and impeller/mixing mechanics are the most crowded claim territory, while process-chemistry-adjacent claims are comparatively open.
Has filing activity in single-use bioreactor scale-up slowed down?
The peak year in this dataset is 2017 at 10 records, and activity in subsequent years has been lower. It is not possible to say from this data alone whether that reflects a maturing technology or simply the roughly 18-month lag between filing and publication understating the most recent one to two years. A growth rate cannot be computed reliably from fewer than four complete recent years.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Single-Use Bioreactor Scale-Up covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.